JP2021519289A5 - - Google Patents
Info
- Publication number
- JP2021519289A5 JP2021519289A5 JP2020551503A JP2020551503A JP2021519289A5 JP 2021519289 A5 JP2021519289 A5 JP 2021519289A5 JP 2020551503 A JP2020551503 A JP 2020551503A JP 2020551503 A JP2020551503 A JP 2020551503A JP 2021519289 A5 JP2021519289 A5 JP 2021519289A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- cancer
- cytotoxic
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023216572A JP2024045111A (ja) | 2018-03-27 | 2023-12-22 | ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862648888P | 2018-03-27 | 2018-03-27 | |
| US201862648880P | 2018-03-27 | 2018-03-27 | |
| US62/648,888 | 2018-03-27 | ||
| US62/648,880 | 2018-03-27 | ||
| PCT/US2019/024111 WO2019191125A1 (en) | 2018-03-27 | 2019-03-26 | Methods of making and using guidance and navigation control proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023216572A Division JP2024045111A (ja) | 2018-03-27 | 2023-12-22 | ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519289A JP2021519289A (ja) | 2021-08-10 |
| JP2021519289A5 true JP2021519289A5 (cg-RX-API-DMAC7.html) | 2022-05-11 |
Family
ID=68060498
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551503A Pending JP2021519289A (ja) | 2018-03-27 | 2019-03-26 | ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 |
| JP2020551549A Active JP7573441B2 (ja) | 2018-03-27 | 2019-03-26 | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 |
| JP2023216572A Pending JP2024045111A (ja) | 2018-03-27 | 2023-12-22 | ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 |
| JP2024180215A Active JP7781243B2 (ja) | 2018-03-27 | 2024-10-15 | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551549A Active JP7573441B2 (ja) | 2018-03-27 | 2019-03-26 | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 |
| JP2023216572A Pending JP2024045111A (ja) | 2018-03-27 | 2023-12-22 | ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 |
| JP2024180215A Active JP7781243B2 (ja) | 2018-03-27 | 2024-10-15 | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12029761B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3773621A4 (cg-RX-API-DMAC7.html) |
| JP (4) | JP2021519289A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20200135935A (cg-RX-API-DMAC7.html) |
| CN (5) | CN111527108A (cg-RX-API-DMAC7.html) |
| AU (4) | AU2019243453B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3094997A1 (cg-RX-API-DMAC7.html) |
| IL (4) | IL312224B2 (cg-RX-API-DMAC7.html) |
| SG (2) | SG11202008474QA (cg-RX-API-DMAC7.html) |
| TW (2) | TW201945013A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2019191125A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11787863B2 (en) * | 2017-06-25 | 2023-10-17 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
| EP3645741A4 (en) * | 2017-06-25 | 2021-08-25 | Systimmune, Inc. | ANTI-4-1BB ANTIBODIES AND METHOD OF MANUFACTURING AND USING |
| US20260008861A9 (en) * | 2017-06-25 | 2026-01-08 | Systimmune, Inc. | Anti-4-1bb antibodies and methods of making and using thereof |
| SG11201912865VA (en) * | 2017-06-25 | 2020-01-30 | Systimmune Inc | Multi-specific antibodies and methods of making and using thereof |
| JP7383605B2 (ja) * | 2017-06-25 | 2023-11-20 | システィミューン, インク. | 抗pd-l1抗体とその作製及び使用方法 |
| TW201904588A (zh) * | 2017-06-25 | 2019-02-01 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質之製造及使用方法 |
| EP3773621A4 (en) * | 2018-03-27 | 2022-03-23 | Systimmune, Inc. | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE |
| CN118580364A (zh) * | 2019-11-06 | 2024-09-03 | 西雅图免疫公司 | 制导和导航控制蛋白及其制备和使用方法 |
| CA3171363A1 (en) * | 2019-12-20 | 2021-06-24 | Kisoji Biotechnology Inc. | Polypeptides, protein complexes and method for making same |
| CA3173980A1 (en) * | 2020-03-03 | 2021-09-10 | Systimmune, Inc. | Anti-cd19 antibodies and methods of using and making thereof |
| TWI908779B (zh) * | 2020-03-17 | 2025-12-21 | 美商西雅圖免疫公司 | 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法 |
| BR112023005152A2 (pt) * | 2020-09-21 | 2023-04-25 | Systimmune Inc | Anticorpo biespecífico com especificidade intensificada (seba) |
| CA3202891A1 (en) | 2021-01-28 | 2022-08-04 | Kara Olson | Compositions and methods for treating cytokine release syndrome |
| US20240262930A1 (en) * | 2021-05-28 | 2024-08-08 | Xyone Therapeutics Inc. | Multi-specific antibody constructs against the muc1-c/extracellular domain (muc1-c/ed) |
| US12559576B2 (en) | 2021-11-11 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | CD20-PD1 binding molecules and methods of use thereof |
| CN118974091A (zh) * | 2022-04-11 | 2024-11-15 | 阿斯利康(瑞典)有限公司 | T细胞结合蛋白 |
| AU2023254191A1 (en) | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| AU2024223918A1 (en) | 2023-02-17 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1354600A1 (en) * | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antibody combination useful for tumor therapy |
| US9783601B2 (en) * | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| EP2930188A1 (en) | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
| MX386342B (es) * | 2014-07-25 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Móleculas de unión a her2 y cd3 biespecíficas. |
| WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| ES2688035T3 (es) * | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| WO2016115274A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| CN107531784B (zh) | 2015-04-29 | 2021-08-27 | 生物医学研究所 | 通过多特异性抗体超强力地中和细胞因子和其用途 |
| WO2017011342A1 (en) * | 2015-07-10 | 2017-01-19 | Abbvie Inc. | Igm-or-ige-modified binding proteins and uses thereof |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| IL304871A (en) * | 2016-01-11 | 2023-10-01 | Inhibrx Inc | Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses |
| EP3443006B1 (en) * | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| ES3056995T3 (en) * | 2016-04-13 | 2026-02-25 | Vivia Biotech Sl | Ex vivo bite-activated t cells |
| EP4166161B1 (en) * | 2016-04-14 | 2026-03-04 | Fred Hutchinson Cancer Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| SG11201808457PA (en) * | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| CN106589129B (zh) | 2016-12-30 | 2021-03-05 | 上海近岸生物科技有限公司 | 一种结合cd19、cd3和cd28的三功能分子及其应用 |
| TW201904588A (zh) * | 2017-06-25 | 2019-02-01 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質之製造及使用方法 |
| SG11201912865VA (en) * | 2017-06-25 | 2020-01-30 | Systimmune Inc | Multi-specific antibodies and methods of making and using thereof |
| US11787863B2 (en) * | 2017-06-25 | 2023-10-17 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
| EP3773621A4 (en) * | 2018-03-27 | 2022-03-23 | Systimmune, Inc. | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE |
-
2019
- 2019-03-26 EP EP19775882.4A patent/EP3773621A4/en active Pending
- 2019-03-26 AU AU2019243453A patent/AU2019243453B2/en active Active
- 2019-03-26 WO PCT/US2019/024111 patent/WO2019191125A1/en not_active Ceased
- 2019-03-26 EP EP19776947.4A patent/EP3774918A4/en active Pending
- 2019-03-26 KR KR1020207019088A patent/KR20200135935A/ko active Pending
- 2019-03-26 CN CN201980006977.5A patent/CN111527108A/zh active Pending
- 2019-03-26 IL IL312224A patent/IL312224B2/en unknown
- 2019-03-26 CA CA3094997A patent/CA3094997A1/en active Pending
- 2019-03-26 SG SG11202008474QA patent/SG11202008474QA/en unknown
- 2019-03-26 IL IL319102A patent/IL319102A/en unknown
- 2019-03-26 JP JP2020551503A patent/JP2021519289A/ja active Pending
- 2019-03-26 US US17/040,513 patent/US12029761B2/en active Active
- 2019-03-26 CN CN202311257564.9A patent/CN117285641A/zh active Pending
- 2019-03-26 IL IL271325A patent/IL271325B2/en unknown
- 2019-03-26 AU AU2019243448A patent/AU2019243448B2/en active Active
- 2019-03-26 WO PCT/US2019/024105 patent/WO2019191120A1/en not_active Ceased
- 2019-03-26 JP JP2020551549A patent/JP7573441B2/ja active Active
- 2019-03-26 CN CN202410657080.1A patent/CN118580363A/zh active Pending
- 2019-03-26 KR KR1020207019089A patent/KR20200139130A/ko active Pending
- 2019-03-26 US US17/040,519 patent/US20210008113A1/en active Pending
- 2019-03-26 SG SG11202008470WA patent/SG11202008470WA/en unknown
- 2019-03-26 IL IL271348A patent/IL271348B2/en unknown
- 2019-03-26 CN CN201980006846.7A patent/CN111566127B/zh active Active
- 2019-03-26 CA CA3094996A patent/CA3094996A1/en active Pending
- 2019-03-26 CN CN202311257825.7A patent/CN117285642A/zh active Pending
- 2019-03-27 TW TW108110699A patent/TW201945013A/zh unknown
- 2019-03-27 TW TW108110660A patent/TW202003037A/zh unknown
-
2023
- 2023-12-22 JP JP2023216572A patent/JP2024045111A/ja active Pending
-
2024
- 2024-08-02 AU AU2024205487A patent/AU2024205487A1/en active Pending
- 2024-08-02 AU AU2024205484A patent/AU2024205484A1/en active Pending
- 2024-10-15 JP JP2024180215A patent/JP7781243B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Novel strategies for cancer immunotherapy: counter-immunoediting therapy | |
| Liu et al. | mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion | |
| Vivier et al. | Natural killer cell therapies | |
| Paijens et al. | Tumor-infiltrating lymphocytes in the immunotherapy era | |
| Liu et al. | Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor | |
| Jin et al. | CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers | |
| Leong et al. | B cells in lung cancer—not just a bystander cell: a literature review | |
| Choi et al. | Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice | |
| Mottok et al. | Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies | |
| Rotiroti et al. | Targeting CD33 in chemoresistant AML patient-derived xenografts by CAR-CIK cells modified with an improved SB transposon system | |
| US20220008464A1 (en) | Modified t cell, preparation method therefor and use thereof | |
| Maki et al. | NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G | |
| Shiozawa et al. | Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells | |
| Oh et al. | Targeting cyclin D-CDK4/6 sensitizes immune-refractory cancer by blocking the SCP3–NANOG axis | |
| JP2021502330A (ja) | Tigitおよび/またはcd112rを標的とするか、またはcd226過剰発現を含む、組成物および免疫治療の方法 | |
| Bisig et al. | New biomarkers in T-cell lymphomas | |
| Moreno-Lama et al. | Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice | |
| Ramesh et al. | Chimeric antigen receptor T‐cells: Properties, production, and quality control | |
| Zhu et al. | CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside | |
| Sim et al. | Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development | |
| Adachi et al. | Cullin-5 deficiency promotes chimeric antigen receptor T cell effector functions potentially via the modulation of JAK/STAT signaling pathway | |
| Suzuki et al. | Activation of STING in pancreatic cancer-associated fibroblasts exerts an antitumor effect by enhancing tumor immunity | |
| Nedelkovska et al. | Follicular lymphoma tregs have a distinct transcription profile impacting their migration and retention in the malignant lymph node | |
| Aqaqe et al. | An ERG enhancer–based reporter identifies leukemia cells with elevated leukemogenic potential driven by ERG-USP9X feed-forward regulation | |
| Kim et al. | Comparison of the different anti-CD16 antibody clones in the activation and expansion of peripheral blood NK cells |